Vaxart (OTCMKTS:VXRT – Get Free Report) released its quarterly earnings results on Thursday. The biotechnology company reported ($0.06) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.06, Zacks reports. The business had revenue of $27.18 million during the quarter, compared to the consensus estimate of $26.21 million. Vaxart had a net margin of 15.88% and a return on equity of 55.48%.
Vaxart Stock Performance
Shares of OTCMKTS VXRT traded down $0.02 during midday trading on Friday, hitting $0.55. The company’s stock had a trading volume of 201,629 shares, compared to its average volume of 299,096. Vaxart has a 1-year low of $0.30 and a 1-year high of $0.84. The firm’s fifty day moving average price is $0.56 and its 200-day moving average price is $0.63. The firm has a market cap of $133.68 million, a P/E ratio of 3.44 and a beta of 1.10.
Wall Street Analysts Forecast Growth
Separately, Zacks Research upgraded shares of Vaxart to a “hold” rating in a research note on Thursday, July 9th. One investment analyst has rated the stock with a Hold rating, Based on data from MarketBeat.com, Vaxart currently has a consensus rating of “Hold”.
Institutional Investors Weigh In On Vaxart
Institutional investors and hedge funds have recently bought and sold shares of the business. Marshall Wace LLP bought a new position in Vaxart in the second quarter worth about $794,000. Jones Financial Companies Lllp grew its holdings in shares of Vaxart by 276,364.7% during the first quarter. Jones Financial Companies Lllp now owns 478,284 shares of the biotechnology company’s stock valued at $196,000 after purchasing an additional 478,111 shares during the last quarter. Raymond James Financial Inc. raised its position in shares of Vaxart by 16.9% during the 2nd quarter. Raymond James Financial Inc. now owns 236,166 shares of the biotechnology company’s stock worth $107,000 after purchasing an additional 34,075 shares during the period. Invesco Ltd. raised its position in shares of Vaxart by 93.1% during the 1st quarter. Invesco Ltd. now owns 146,366 shares of the biotechnology company’s stock worth $60,000 after purchasing an additional 70,568 shares during the period. Finally, Goldman Sachs Group Inc. bought a new stake in shares of Vaxart in the 1st quarter worth approximately $31,000. Institutional investors and hedge funds own 18.05% of the company’s stock.
About Vaxart
Vaxart, Inc is a clinical-stage biotechnology company pioneering the development of oral recombinant vaccines administered in tablet form. Leveraging a proprietary, room-temperature-stable platform, the company aims to simplify vaccine delivery while eliciting both systemic and mucosal immune responses. Its technology is based on the replication-defective adenovirus vector system, which encodes target antigens designed to protect against a range of infectious diseases without the need for injections or cold-chain logistics.
The company’s pipeline includes multiple vaccine candidates in various stages of development.
Featured Stories
- Five stocks we like better than Vaxart
- Quantum Earnings Week: Winners and Losers Are Finally Emerging
- Axon’s Post-Earnings Pullback May Be More About Valuation Than Growth
- Uber Stock Lags in 2026, But Cash Flow and AV Bets Fuel Upside
- AppLovin Stock Hits 52-Week Low as Analysts Trim Targets, Stay Bullish
Receive News & Ratings for Vaxart Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxart and related companies with MarketBeat.com's FREE daily email newsletter.
